Sigma Planning Corp Takes Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Sigma Planning Corp bought a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA) in the 3rd quarter, HoldingsChannel.com reports. The firm bought 15,000 shares of the biotechnology company’s stock, valued at approximately $300,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ADMA. Quest Partners LLC bought a new position in ADMA Biologics in the second quarter worth approximately $29,000. Hollencrest Capital Management bought a new position in shares of ADMA Biologics in the 3rd quarter worth $30,000. EntryPoint Capital LLC acquired a new stake in ADMA Biologics in the 1st quarter valued at $31,000. CWM LLC increased its stake in ADMA Biologics by 114.2% during the 2nd quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock valued at $92,000 after purchasing an additional 4,367 shares in the last quarter. Finally, Acadian Asset Management LLC bought a new stake in ADMA Biologics during the 2nd quarter valued at $93,000. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Stock Down 5.7 %

ADMA Biologics stock opened at $19.04 on Friday. ADMA Biologics, Inc. has a fifty-two week low of $3.60 and a fifty-two week high of $23.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The firm’s 50-day simple moving average is $18.54 and its 200 day simple moving average is $14.34. The stock has a market cap of $4.44 billion, a PE ratio of 68.00 and a beta of 0.64.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. The firm had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same quarter in the previous year, the business earned $0.01 EPS. Research analysts predict that ADMA Biologics, Inc. will post 0.52 EPS for the current fiscal year.

Insider Buying and Selling at ADMA Biologics

In related news, CEO Adam S. Grossman sold 236,889 shares of the business’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the sale, the chief executive officer now directly owns 2,059,726 shares in the company, valued at approximately $36,436,552.94. The trade was a 10.31 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Lawrence P. Guiheen sold 9,000 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $18.47, for a total transaction of $166,230.00. Following the completion of the sale, the director now directly owns 153,941 shares in the company, valued at approximately $2,843,290.27. This trade represents a 5.52 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 466,900 shares of company stock worth $8,224,121 in the last quarter. 3.70% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms have recently commented on ADMA. Raymond James boosted their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research report on Friday, November 8th. Cantor Fitzgerald reissued an “overweight” rating and set a $20.00 price objective on shares of ADMA Biologics in a report on Friday, September 20th. Finally, HC Wainwright raised their target price on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a report on Friday, November 8th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.